Details of the Drug

General Information of Drug (ID: DMFJH5Q)

Drug Name
Mephentermine
Synonyms
Mefenterdrin; Mefentermin; Mefentermina; Mephenterdrine; Mephenterdrinum; Mephenterminum; Mephetedrine; Mephine; Vialin; Wyamine; Wyfentermina; Mefentermina [INN-Spanish]; Mephentermine (INN); Mephentermine [INN:BAN]; Mephenterminum [INN-Latin]; N-Methylphentermine; WY-585; Mephentermine Sulfate (2:1); N,alpha,alpha-Trimethylbenzeneethanamine; N,alpha,alpha-Trimethylphenethylamine; Omega-Phenyl-tert-butyl-methylamine; N-Methyl-omega-phenyl-t-butylamine; N-Methyl-omega-phenyl-tert-butylamine; N,2-dimethyl-1-phenylpropan-2-amine; 2-Methyl-2-methylamino-1-phenylpropane; 2-Methylamino-2-methyl-1-phenylpropane
Indication
Disease Entry ICD 11 Status REF
High blood pressure BA00 Approved [1]
Therapeutic Class
Vasoconstrictor Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 163.26
Topological Polar Surface Area (xlogp) 2.4
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 17 - 18 hours [2]
Metabolism
The drug is metabolized via the hepatic [3]
Chemical Identifiers
Formula
C11H17N
IUPAC Name
N,2-dimethyl-1-phenylpropan-2-amine
Canonical SMILES
CC(C)(CC1=CC=CC=C1)NC
InChI
InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
InChIKey
RXQCGGRTAILOIN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3677
ChEBI ID
CHEBI:6755
CAS Number
100-92-5
DrugBank ID
DB01365
TTD ID
D0G1OZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease High blood pressure
ICD Disease Classification BA00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D2 receptor (D2R) DTT DRD2 2.50E-02 -0.08 -0.49
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mephentermine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Increased risk of hyperpyrexia by the combination of Mephentermine and Methylene blue. Acquired methaemoglobinaemia [3A93] [15]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Mephentermine and Droxidopa. Autonomic nervous system disorder [8D87] [16]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Mephentermine and Levomilnacipran. Chronic pain [MG30] [17]
Milnacipran DMBFE74 Moderate Additive hypertensive effects by the combination of Mephentermine and Milnacipran. Depression [6A70-6A7Z] [17]
Desvenlafaxine DMHD4PE Moderate Increased risk of rapid heart rate by the combination of Mephentermine and Desvenlafaxine. Depression [6A70-6A7Z] [17]
Ozanimod DMT6AM2 Moderate Increased risk of hyperpyrexia by the combination of Mephentermine and Ozanimod. Multiple sclerosis [8A40] [15]
Safinamide DM0YWJC Moderate Decreased metabolism of Mephentermine caused by Safinamide mediated inhibition of non-CYP450 enzyme. Parkinsonism [8A00] [18]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Mephentermine and Rasagiline. Parkinsonism [8A00] [15]
⏷ Show the Full List of 8 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4.
5 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
6 Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
7 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
8 Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
9 Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
11 Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
12 [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
13 Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
14 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
15 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
16 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
17 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
18 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".